DDInter283 DDInter899
Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Cangrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Cangrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Cangrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Cangrelor {u} may lead to a major life threatening interaction when taken with {v} Alteplase
Cangrelor {u} may lead to a major life threatening interaction when taken with {v} Tinzaparin
Cangrelor may cause a minor interaction that can limit clinical effects when taken with Turmeric
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Cangrelor may lead to a major life threatening interaction when taken with Alteplase
Cangrelor may lead to a major life threatening interaction when taken with Tinzaparin